Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A polypeptide for inhibiting focal adhesion kinase and its application

A focal adhesion kinase and sequence technology, applied in the direction of peptides, desipeptides, peptide/protein components, etc., can solve the problems of limited development, short half-life in vivo, and lack of specificity of small molecule inhibitors, so as to increase survival rate and improve Survival effect

Inactive Publication Date: 2016-03-30
ZHEJIANG YUANTAI BIOTECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The preparation and use of macromolecular inhibitors limits their development, such as the short in vivo half-life of recombinant human focal adhesion kinase inhibitor
Many successful small-molecule inhibitors can inhibit the activity of FAK at the nanomolar level, but small-molecule inhibitors lack specificity, and long-term use of FAK inhibitors lacking specificity in chronic diseases may produce major side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Inhibition of the effect of focal adhesion kinase polypeptides on focal adhesion kinase activity in vitro.

[0017] Take fresh bovine brain tissue, peel off the meninges and large blood vessels, cut into pieces, wash 1-2 times with cold MES buffer, add MES buffer at a ratio of 0.5-1ml per gram of brain tissue, and at 4°C, use electric Homogenize with a homogenizer; centrifuge at 105,000 g for 1 h at 4°C, take the supernatant, add an equal volume of microtube polymerization buffer, and incubate in a water bath at 37°C for 30 min. Centrifuge at 105,000 g at 26°C for 1 hour, take the precipitate, add about 1 / 10 of the homogenate volume of cold MES buffer, stir gently or crush the precipitate with a homogenizer; place the suspension in an ice bath for 30 min to dissolve the precipitate completely. Protein content was determined by Lowry's method (SDS polyamide gel electrophoresis). Adhesion kinase was diluted to 4-5mg / ml with MES buffer and stored in liquid nitrogen. Take...

Embodiment 2

[0021] Inhibiting the growth and survival IC50 of focal adhesion kinase polypeptide on the growth and survival of tumor cells cultured in vitro.

[0022] The MTT colorimetric method was used. The logarithmic growth of U937 cells was added to a 96-well culture plate at 1.0×105, and cultured for 24 hours. The experimental wells and the positive drug control wells were respectively added with different concentrations of the experimental drug inhibiting focal adhesion kinase polypeptide and the positive control drug vincristine; The same volume of solvent was added to the blank group. Set up five duplicate wells per well, culture for 48h, add MTT to each well at 0h, 2h, 8h, 14h, 20h, 24h, 36h, and 48h respectively, add DMSO after 4h of action, incubate for 30min, and incubate at 620nm in a microplate reader Measure the absorbance A value, according to the formula tumor cell growth inhibition rate=(1-absorbance value of the experimental group / absorbance value of the control group)...

Embodiment 3

[0024] The in vivo activity of the polypeptides inhibiting focal adhesion kinase was detected by tumor model.

[0025] The U937 tumor model was established, and the positive control drug was vincristine; the same volume of solvent was added to the blank group, and 3 doses were set to the experimental group: 0.75, 1.5 μM, and 3 μM mg / Kg. After 21 days, the number of surviving mice was observed, and the survival rate was calculated. The results showed that inhibiting the focal adhesion kinase polypeptide can effectively protect mice and improve the survival rate of tumor-bearing mice, with the survival rate reaching 83.31%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to a polypeptide capable of inhibiting the activity of adhesion plaque kinase and treating acute lymphocytic leukemia. Its sequence is ADLIDGYRLVNGTSQRALERLV is a brand-new sequence, they can inhibit the activity of focal adhesion kinase in vitro, and improve the survival rate of tumor-bearing mice in vivo, and have potential new drug development value.

Description

technical field [0001] The invention relates to a polypeptide for inhibiting adhesion plaque kinase and its application, in particular to a polypeptide which has the activity of inhibiting adhesion plaque kinase and can treat acute lymphocytic leukemia. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a progressive malignant disease characterized by large numbers of immature white blood cells that resemble lymphoblasts. These cells can be found in the blood, bone marrow, lymph nodes, spleen and other organs. Acute lymphoblastic leukemia accounts for 80% of acute leukemia in children, and the peak incidence is between 3 and 7 years old. ALL can also occur in adults and accounts for 20% of all adult leukemias. In recent years, with the deepening of medical research, great progress has been made in the understanding and treatment of acute lymphoblastic leukemia. Among them, focal adhesion kinase plays an important role in acute lymphoblastic leukemia. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/00A61K38/16A61P35/02
CPCA61K38/00C07K14/00
Inventor 徐永军
Owner ZHEJIANG YUANTAI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com